BI 1015550 Improves Silica-Induced Silicosis and LPS-Induced Acute Lung Injury in Mice
Molecules · 14.03.2025 · 30 (6) · 1311
DOI: 10.3390/molecules30061311 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, online erschienen am 14.03.2025. Verfasst von Yuming Liu und 8 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy, Nankai University, Tianjin 300353, China. Hauptthemen laut MEDLINE: Silicosis, Acute Lung Injury, Lipopolysaccharides, Silicon Dioxide. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Science and Technology SMEs Innovation Ability Improvement Project of Shandong Province, The National Natural Science Foundation of China.
Abstract (Originalsprache)
Silicosis is an interstitial lung disease (ILD) caused by prolonged inhalation of silica particles. Acute lung injury (ALI) is a critical clinical syndrome involving bilateral lung infiltration and acute hypoxic respiratory failure. However, there is currently no effective treatment for these two diseases. Previous research has established that cyclic adenosine monophosphate (cAMP) is pivotal in the pathogenesis of silicosis and acute lung injury. Phosphodiesterase 4 (PDE4) is a hydrolase enzyme of cAMP, and BI 1015550, as an inhibitor of PDE4B, is expected to be a candidate drug for treating both. BI 1015550 has shown certain anti-inflammatory and anti-fibrotic properties in systemic sclerosis-associated interstitial lung disease (SSc-ILD) and idiopathic pulmonary fibrosis (IPF), but there is a lack of research on silicosis and acute lung injury. In this research, we successfully synthesized BI 1015550 autonomously and demonstrated that it could significantly improve lung fibrosis and inflammation in a silica-induced silicosis mouse model. Furthermore, we found that BI 1015550 could also alleviate lung inflammation in a Lipopolysaccharide (LPS)-induced acute lung injury mouse model. The mechanism of action may involve the regulation of cAMP-related signaling pathways.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy, Nankai University, Tianjin 300353, China.
- School of Life Sciences and Medicine, Shandong University of Technology, Zibo 255049, China.
- Tianjin Key Laboratory of Molecular Drug Research, Tianjin International Joint Academy of Biomedicine, Tianjin 300457, China.
ORCID-Profile: Feng Sang
Förderung
- the Science and Technology SMEs Innovation Ability Improvement Project of Shandong Province
- The National Natural Science Foundation of China
Zitieren
APA
Liu, Y., Zhang, J., Hu, Y., Liu, Z., Yang, Z., Jiao, R., Liu, X., Li, X., & Sang, F. (2025). BI 1015550 Improves Silica-Induced Silicosis and LPS-Induced Acute Lung Injury in Mice. Molecules, 30(6), 1311. https://doi.org/10.3390/molecules30061311
Vancouver
Liu Y, Zhang J, Hu Y, Liu Z, Yang Z, Jiao R, et al. BI 1015550 Improves Silica-Induced Silicosis and LPS-Induced Acute Lung Injury in Mice. Molecules. 2025;30(6):1311. doi:10.3390/molecules30061311
BibTeX
@article{Liu2025,
author = {Liu, Yuming and Zhang, Jing and Hu, Yayue and Liu, Zhigang and Yang, Zhongyi and Jiao, Ran and Liu, Xueze and Li, Xiaohe and Sang, Feng},
title = {BI 1015550 Improves Silica-Induced Silicosis and LPS-Induced Acute Lung Injury in Mice},
journal = {Molecules},
year = {2025},
volume = {30},
number = {6},
pages = {1311},
doi = {10.3390/molecules30061311}
}
EUVIMED